1 BRIEF REPORT

- 2 Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test
- 3 Device) for the diagnosis of COVID-19 in primary healthcare centers
- 4 Eliseo Albert, Ignacio Torres, Felipe Bueno, Dixie Huntley, Estefanía Molla,
- 5 Miguel Ángel Fernández-Fuentes, Mireia Martínez, Sandrine Poujois, Lorena
- 6 Forqué, 1 Arantxa Valdivia, 1 Carlos Solano de la Asunción, 1 Josep Ferrer, 1 Javier
- 7 Colomina² and David Navarro^{1,3*}
- 8 ¹Microbiology Service, Hospital Clínico Universitario, INCLIVA Research Institute,
- 9 Valencia, Spain.
- 10 ²Instituto Valenciano de Microbiología, Bétera, Valencia, Spain.
- ³Department of Microbiology, School of Medicine, University of Valencia, Valencia,
- 12 Spain.
- 13 **Keywords:** SARS-CoV-2, COVID-19, rapid antigen test (RAD), primary healthcare
- 14 center.

16

22

- 15 **Running title:** Rapid antigen detection assay for diagnosis of COVID-19.
- 17 *Correspondence: David Navarro, Microbiology Service, Hospital Clínico
- 18 Universitario, Instituto de Investigación INCLIVA, Valencia, and Department of
- 19 Microbiology, University of Valencia, Valencia, Spain. Av. Blasco Ibáñez 17, 46010
- 20 Valencia, Spain. Phone: 34(96)1973500; Fax: 34(96)3864173; E-mail:
- 21 david.navarro@uv.es.

Abstract

24

30

- 25 We evaluated the Panbio[™] COVID-19 AG Rapid Test Device (RAD) for the diagnosis
- of COVID-19 in symptomatic patients attended in primary healthcare centers (n=412).
- 27 Overall specificity and sensitivity of RAD was 100% and 79.6%, respectively, taking
- 28 RT-PCR as the reference. SARS-CoV-2 could not be cultured from specimens yielding
- 29 RT-PCR+/RAD- results.

Introduction

- 31 Rapid detection, effective isolation of symptomatic cases and systematic tracing of close
- 32 contacts are paramount to blunt community spread of SARS-CoV-2 infection.
- 33 Nowadays, reverse □ transcriptase polymerase chain reaction (RT□PCR) is the
- 34 diagnostic "gold standard" for COVID-19 [1]; nevertheless, specialized instrument and
- 35 expertise are required to conduct RT-PCR assays. In addition, supply shortages of RT-
- 36 PCR reagents have been encountered by many countries. Rapid antigen detection
- 37 (RAD) immunoassays are particularly suited for point of care testing (POC), as they can
- 38 be easily performed and interpreted without equipment, are low cost, and improve the
- 39 turn-around time for results. Moreover, results obtained by a recently launched antigen
- 40 assay appeared to correlate better with patient infectiousness than those returned by RT-
- 41 PCR [2]. In this field study, we evaluated the PanbioTM COVID-19 AG Rapid Test
- 42 Device (Abbott Diagnostic GmbH, Jena, Germany), a lateral flow
- 43 immunochromatographic assay targeting SARS-CoV-2 nucleoprotein in
- 44 nasopharyngheal (NP) specimens for diagnosis of COVID-19 in symptomatic patients
- 45 attended in primary healthcare centers.

46 Material and methods

47 Patients

48 This prospective study included 412 patients (median age, 31 years; range, 1-91; 58%

49 females), of whom 327 were adults (median, 36 years; range, 17-91) and 85 pediatrics

(≤16 years old; median, 11 years; range, 1-16), with clinical suspicion of COVID-19

attended in primary care centers (n=8) of the Health Department Clínico-Malvarrosa in

52 Valencia. Only patients with compatible signs or symptoms appearing within the prior

53 week (0-7 days) were recruited. The study was conducted between September 2nd and

October 7th 2020. The study was approved by the Hospital Clínico Universitario (HCU)

55 INCLIVA Ethics Committee.

56 SARS-CoV-2 testing

50

51

57 Trained nurses at each participating center collected two NP per patient using flocked

58 swabs following appropriate safety precautions, one of which (provided by the

59 manufacturer) was used for RAD and the other was placed in 3□mL of universal

60 transport medium-UTM-(Becton Dickinson, Sparks, MD) and delivered to the

61 Microbiology Service of HCU for RT-PCR testing. RAD was performed immediately

62 after sampling following the instructions of the manufacturer (reading at 15 min.). RT-

PCRs were carried out within 24 h. of specimen collection with the TaqPath COVID-19

64 Combo Kit (Thermo Fisher Scientific, Massachusetts, USA), which targets SARS-CoV-

65 2 ORF1ab, N and S genes. RNA was extracted using the Applied BiosystemsTM

66 MagMAXTM Viral/Pathogen II Nucleic Acid Isolation Kits coupled with Thermo

67 ScientificTM KingFisher Flex automated instrument (Thermo Fisher Scientific). The

68 AMPLIRUN® TOTAL SARS-COV-2 Control (Vircell S.A:, Granada, Spain-) was

69 used as the reference material for SARS-CoV-2 RNA load quantitation (in copies/ml,

70 considering RT-PCR C_{Ts} for the N gene: the linear regression equation was: Y = -

71 0.31*X + 13.77; $R^2 = 9.89$).

72 SARS-CoV-2 cell culture

Samples collected in UTM were stored at -80°C for up to 2 weeks before being 73 74 processed for culture. Vero E6 cells, maintained in Modified Eagles Medium (MEM) 75 supplemented with 5% Fetal Bovine Serum (FBS), 1% penicillin/ streptomycin, 0.5 76 µg/mL Amphotericin B and 1% L-glutamine, were seeded into 96 well plates (Thermo Fisher Scientific) at 10⁵ cells/ml and inoculated in triplicate with patient samples (100 77 78 μl of a 1:1 dilution in MEM 2% FBS supplemented with antibiotics). Cultures were 79 incubated at 37°C with 5% CO₂ for 4 days. Blind subcultures were performed at 48 h and incubated for another 4 days. Cytopathic effect (CPE) was evaluated daily and 80 81 recorded. The presence of SARS-CoV-2 was confirmed by RT-PCR (performed at time 82 0, and days 2 and 4). 83 Statistical analyses RAD was evaluated for its sensitivity and specificity with the associated 95% 84 confidence intervals (CI) using RT-PCR as the reference. Negative predictive value 85 (NPV) and positive predictive value (PPV) were calculated for prevalences of SARS-86 87 CoV-2 infection of 5% and 10%, according to that in our Health Department within the 88 study period. Agreement between RAD and RT-PCR was assessed using Cohen's Kappa (κ) statistics. Differences between medians were compared using the Mann-89 90 Whitney U-test. Receiver operating characteristic curves were built to determine SARS-91 CoV-2 RT-PCR cycle threshold (C_T) and RNA loads best discriminating between RT-92 PCR+/RAD+ or RAD- specimens. Two-sided P-values <0.05 were considered 93 significant. Statistical analyses were performed using SPSS version 25.0 (SPSS, 94 Chicago, IL, USA).

Results

- 96 Out of 412 patients, 43 tested positive by RT-PCR and RAD (10.4%) and 358 (86.9%)
- 97 negative by both methods. Discordant results (RT-PCR+/RAD-) were noticed in 11
- patients (2.7%). Characteristics of these patients are shown in Supplementary Table 1.
- 99 There were no RT-PCR-/RAD+ specimens. Concordance between both methods was
- 100 good (κ, 0.87; 95% CI, 0.79-0.94). Accordingly, overall specificity and sensitivity of
- 101 RAD was 100% (95% CI, 98.7-100%), and 79.6% (95% CI, 67.-88.8%), respectively.
- Sensitivity slightly increased (80.4%; 95% CI, 66.8-89.3%) in patients with clinical
- courses shorter than 5 days (Figure 1A).
- The sensitivity was higher in adults (82.6%; 95% CI, 69.3-90.9%) than in pediatric
- patients (62.5%; 95% CI, 30.6-86.3%). The data are shown in Supplementary Table 2.
- 106 Overall RAD negative predictive value for an estimated prevalence of 5% and 10% was
- 107 99% (95% CI, 97.4-99.6%) and 97.9 (95% CI, 95.9-98.9), respectively.
- 108 RT-PCR C_T values and SARS-COV-2 RNA loads were significantly higher or lower (P
- 109 <0.001), respectively, in RT-PCR+/RAD- than in RT-PCR+/RAD+ specimens (Figure</p>
- 110 1B and 1C).
- 111 ROC curve analyses indicated that RT-PCR C_T <25 and SARS-CoV-2 RNA loads > 5.9
- 112 log₁₀ copies/ml thresholds best discriminated between RT-PCR+/RAD+ and RT-
- 113 PCR+/RAD-/ specimens, with a sensitivity and specificity of 100%
- The time to sampling since the onset of symptoms did not differ (P=0.86) between RT-
- 115 PCR+/RAD+ (median, 3 days; range 1-7 days) and RT-PCR+/RAD- (median 2 days;
- range, 1-6 days) patients.
- Patients with fever, either with or without other accompanying symptoms, tested more
- 118 frequently RT-PCR+/ RAD+ (P=0.02) than afebrile patients (Supplementary Table 3).

119 All 11 specimens yielding discordant RT-PCR/RAD results tested negative by culture,

whereas SARS-CoV-2 could be recovered from 3 out of 3 specimens returning RT-

121 PCR+/RAD+ results (C_T: 4, 14 and 16).

Discussion

120

122

123 Previous studies evaluating SARS-CoV-2 RAD tests either used retrieved specimens, which had been cryopreserved for a wide range of times, were conducted at central 124 125 laboratories or both [3-7]. To our knowledge this is the first report on the performance 126 of a RAD assay conducted at POC. As such, it may provide a realistic view of how 127 implementation of RAD tests in clinical practice can contribute to the management and 128 control of the COVID-19 pandemics. When compared to RT-PCR, the Panbio™ 129 COVID-19 AG Rapid Test Device assay yielded an excellent specificity and a fairly 130 good overall sensitivity (79.6%); the latter slightly improved when the time to testing was less than 5 days since the onset of symptoms (80.6%). This figure is less impressive 131 132 than that claimed by the manufacturer (93%); however it is close (86.5%) to that reported by Linares and colleagues [3] in a mixed cohort including patients attended at 133 134 the Emergency Department or primary healthcare centers and centralized testing at the hospital laboratory. Sensitivity of SARS-CoV-2 RAD assays has been reported to vary 135 136 between 45%-97% [3-7]; yet, direct comparison between studies is hampered by 137 relevant dissimilarities regarding clinical characteristics and age of patients, site of 138 testing, type of specimen processed, and time to testing, among others. 139 Interestingly, the sensitivity was higher in adults (82.6%) than in pediatric patients 140 (62.5%). Previous studies found no age-related differences in SARS-CoV-2 RNA load 141 in the upper respiratory tract [8]. Although speculative, dating the accurate onset of 142 symptoms could have been less reliable in children than in adults.

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

In a setting with an incidence of COVID-19 ranging between 5% and 10% such as ours at the time of the study, the RAD NPV was very good (99% and 97.9%, respectively). There were 11 out of 54 RT-PCR positive specimens that tested negative by RAD. In line with previous reports [2-4], SARS-CoV-2 RNA load in RT-PCR+/ RAD+ specimens was significantly higher than that in RT-PCR+/ RAD- samples. In our setting, specimens with RT-PCR C_T >25 (equivalent to SARS-CoV-2 RNA loads < 5.9 log₁₀ copies/ml) returned discordant RAD/RT-PCR results. We did not observe a major impact of the time to testing on the likelihood of having a positive RAD result. On the other hand, fever was the only clinical feature reported more frequently in patients testing RT-PCR+/RAD+ than in those RT-PCR+/RAD-. A relevant observation of our study was that SARS-CoV-2 could not be cultured from RT-PCR+/RAD- specimens. In line with that, Pekosz and colleagues [2], by using a highly sensitive cell culture system (VeroE6 TMPRSS2), found 1 out of 27 RAD-/culture + specimens. SARS-CoV-2 RNA load threshold associated with culture positivity herein (> 5.9 log₁₀ copies/ml) was remarkably close to others previously published-around 10⁶ copies/ml-[2,9-11]. The main limitation of the current study is the relatively low number of cases in the series (13%); this, however, can be viewed as a strength, as this figure likely represents that found in many community settings worldwide where RAD testing is being increasingly used. In summary, we found the PanbioTM COVID-19 AG Rapid Test Device to perform well as a POC for early diagnosis of COVID-19 in primary healthcare centers. More importantly, our data suggested that patients with RT-PCR-proven COVID-19 testing negative by RAD are unlikely to be infectious. Further studies are warranted to confirm 167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

this assumption. The inconsequentiality of false negative RAD results, from a public health perspective [12], would support the implementation of a laboratory diagnostic approach which excluded confirmatory RT-PCR testing for negative RAD tests in nonhospitalized patients, even when the pretest probability is high. This would certainly alleviate laboratory workloads while dealing with RT-PCR supply shortages. **ACKNOWLEDGMENTS** We are grateful to Abbott Diagnostics for providing PanbioTM COVID-19 AG Rapid Test Device kits. We thank all personnel working at Microbiology Service of Clinic University Hospital for their unwavering commitment in the fight against COVID-19. We also thank María José Beltrán, Pilar Botija and Ana Sanmartín for assistance in the organization of RAD testing in primary healthcare centers. FINANCIAL SUPPORT This work received no public or private funds. **CONFLICTS OF INTEREST** The authors declare no conflicts of interest. **AUTHOR'S CONTRIBUTIONS** EA, IT, FB, DH, MM, SP, LF, AV, CSdA, JP and JC: Methodology (RT-PCR and RAD) and validation of data; EM and MA F-F: Methodology (cell culture) and validation of data. EA, IT: formal analysis. DN: Conceptualization, supervision, writing the original draft. All authors reviewed the original draft.

189 190 **REFERENCES** 1. of 191 Overview **Testing** for SARS-CoV-2 (COVID-19) https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html. 192 Updated September 18. 193 194 2. Pekosz A, Cooper C, Parvu V, Li M, Andrews J, Manabe YC, Kodsi S, Leitch F, 195 Gary D, Roger-Dalbert C. Antigen-based testing but not real-time PCR 196 correlates with SARS-CoV-2 virus culture. medRxiv 2020.10.02.20205708; doi: 197 https://doi.org/10.1101/2020.10.02.20205708. 198 3. Linares M, Pérez-Tanoira R, Romanyk J, et al. Panbio antigen rapid test is 199 reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of doi: 200 symptoms.medRxiv **2020**.09.20.20198192; 201 https://doi.org/10.1101/2020.09.20.20198192. 202 4. Young S, Taylor SN, Cammarata CL, et al. Clinical evaluation of BD Veritor 203 SARS-CoV-2 point-of-care test performance compared to PCR-based testing 204 and versus the Sofia 2 SARS Antigen point-of-care test. J Clin Microbiol. 2020 205 Oct 6:JCM.02338-20. 5. 206 Scohy A, Anantharajah A, Bodéus M, Kabamba-Mukadi B, Verroken A, 207 Rodriguez-Villalobos H. Low performance of rapid antigen detection test as 208 frontline testing for COVID-19 diagnosis. J Clin Virol. 2020 Aug;129:104455. 209 doi: 10.1016/j.jcv.2020.104455.

- 210 6. Lambert-Niclot S, Cuffel A, Le Pape S, et al. Evaluation of a Rapid Diagnostic
- Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. J Clin
- 212 Microbiol. **2020** Jul 23;58(8):e00977-20.
- 213 7. Mak GC, Cheng PK, Lau SS, et al. Evaluation of rapid antigen test for detection
- of SARS-CoV-2 virus. J Clin Virol. **2020** Aug;129:104500. doi:
- 215 10.1016/j.jcv.2020.104500.
- 8. Baggio S, L'Huillier AG, Yerly S, et al. SARS-CoV-2 viral load in the upper
- respiratory tract of children and adults with early acute COVID-19. Clin Infect
- 218 Dis. **2020** Aug 6:ciaa1157.
- 219 9. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of
- hospitalized patients with COVID-2019. Nature. **2020**;581:465-469.
- 221 10. Huang CG, Lee KM, Hsiao MJ, et al. Culture-Based Virus Isolation To Evaluate
- Potential Infectivity of Clinical Specimens Tested for COVID-19. J Clin
- 223 Microbiol. **2020**;58:e01068-20
- 224 11. Bullard J, Dust K, Funk D, et al. Predicting Infectious Severe Acute Respiratory
- Syndrome Coronavirus 2 From Diagnostic Samples. Clin Infect Dis. 2020
- 226 :ciaa638.
- 227 12. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity A
- Strategy for Containment. N Engl J Med. 2020 Sep 30. doi:
- 229 10.1056/NEJMp2025631

231 Figure Legend

Figure 1. (**A**) Field performance of the PanbioTM COVID-19 AG Rapid Test Device (RAD) according to the time of testing since the onset of symptoms (< or \ge 5 days) in a cohort of symptomatic patients with clinical suspicion of COVID-19 attended at primary healthcare centers. (B) RT-PCR C_T values in specimens testing either RAD + or RAD -. (C) SARS-CoV-2 RNA loads in specimens testing either RAD + or RAD-. Median and *P* values are shown.

